Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

771.87 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	765.00 (40)
Ask (Size)	773.00 (40)
Prev. Close	771.87
Today's Range	771.87 - 771.87
52wk Range	476.49 - 792.77
Shares Outstanding	91,779,465
Dividend Yield	0.46%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Via MarketMinute

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

December 30, 2025

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have...

Via StockStory

Performance

YTD	N/A	N/A
1 Month	+2.9%	+2.9%
3 Month	+28.7%	+28.7%
6 Month	+40.9%	+40.9%
1 Year	+8.4%	+8.4%

More News

Discover which S&P500 stocks are making waves on Tuesday. ↗

December 30, 2025

Via Chartmill

3 Cash-Heavy Stocks We Approach with Caution

December 28, 2025

Via StockStory

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

Via PredictStreet

The Atomic Architect: How University of Washington’s Generative AI Just Rewrote the Rules of Medicine

December 24, 2025

Via TokenRing AI

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

Via PredictStreet

Dupixent® (dupilumab) Approved in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

December 23, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

December 22, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

Via Stocktwits

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

Via Stocktwits

Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗

December 16, 2025

Via MarketBeat

2 Large-Cap Stocks on Our Buy List and 1 We Find Risky

December 15, 2025

Via StockStory

2 Reasons to Buy Regeneron Stock Like There's No Tomorrow ↗

December 13, 2025

Via The Motley Fool

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

Via MarketMinute

3 Low-Volatility Stocks We’re Skeptical Of

December 10, 2025

Via StockStory

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

December 07, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

3 Cash-Producing Stocks We Find Risky

December 03, 2025

Via StockStory

Morgan Stanley Downgrades Regeneron (REGN) to Equal-Weight, Citing Fair Valuation and Pipeline Scrutiny

December 03, 2025

Via MarketMinute

Exploring the top movers within the S&P500 index during today's session. ↗

December 01, 2025

Via Chartmill

5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗

December 01, 2025

Via MarketBeat

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

December 01, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Should You Buy This Biotech Stock That Just Gained 5% in 1 Day? ↗

November 30, 2025

Via The Motley Fool

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

November 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 771.87

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 12/31/25 04:00 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 70.84B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 71B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.